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Summary A small pre-treatment 'priming' dose of cyclophosphamide will reduce gut damage due to high
dose i.v. melphalan in mice and sheep but efforts to demonstrate this effect in man have been hampered by
difficulty in the measurement of gut damage. We have evaluated the "CR EDTA absorption test, a new
method for measuring intestinal permeability, as a means of assessing damage due to high dose melphalan.
The test was reliable, with a narrow normal range, easy to use and well tolerated. It detected an increase in
intestinal permeability after high dose melphalan with a maximum occurring between 9 and 15 days after
treatment and subsequently returning to normal. It was shown in 19 patients that a pre-treatment dose of
cyclophosphamide was capable of significantly reducing the abnormalities in intestinal permeability which
resulted from high dose melphalan.
The proliferating epithelium of the intestine is damaged by
some cancer chemotherapy and by radiotherapy (Shaw et al.,
1979). The doses of these treatments which may be given are
frequently limited by gut damage. In studies with high dose
intravenous melphalan it has been shown that when
autologous bone marrow transplantation is used, the toxicity
which prevents further increase in the dose of melphalan is
intestinal damage (McElwain et al., 1979; Cornbleet et al.,
1983). In experimental systems this gut damage can be
reduced by pre-treatment of animals with a 'priming' dose of
cyclophosphamide given 2 days before the melphalan in mice
and 7 days in sheep (Millar et al., 1978).
It has been difficult to evaluate the priming effect in man
because of the absence of an acceptable method for
measuring intestinal damage. Simple conventional methods
for measuring gut damage appear to be insensitive or
unreliable when applied to the measurement of cytotoxic
effects. More elaborate or invasive methods cannot be
readily used in this patient population who are usually
unwell and predisposed to infection or bleeding. For
example, although studies at this hospital using a simple
xylose absorption test have shown functional abnormalities
after methotrexate given for maintenance treatment in acute
childhood leukaemia (Craft et al., 1977), we have found this
test to be poorly tolerated and unreliable in patients
receiving more intensive treatments.
The 5"chromium edetic acid (EDTA) absorption test was
introduced as a sensitive, reliable and valid measurement for
intestinal permeability in patients with coeliac disease
(Bjarnason et al., 1983; Bjarnason & Peters, 1984; Editorial,
1985). EDTA is an inert molecule which is normally
absorbed from the intestine in very small quantities. Damage
to the epithelium renders it more permeable allowing
increased absorption into the blood stream, probably
between cells rather than by an intracellular uptake. Subse-
quently the molecule is filtered in the kidneys and excreted in
the urine. Increased excretion of 5"chromium EDTA in urine
after an oral dose indicates increased intestinal permeability
(Selby et al., 1984).
The principal purposes of the present study were two fold.
Firstly we wished to evaluate the 51CR EDTA test as a
novel method for measuring cytotoxic damage to the gut
epithelium. Secondly, we used it to see if we could
demonstrate the priming effect of gut in man.
Methods and patients
Informed consent was obtained. Patients fasted from
midnight and emptied their bladders before the test. A
sample of this urine was used to measure background
activity. At 9 am IIchromium EDTA (specific activity
37 MBq 10 ml-1, Amersham, Bucks; half life 27.7 days)
prepared to activity of 4 MBq was drunk by the patient in a
tasteless, odourless drink followed by 100 ml of water. An
aliquot of the "1Cr EDTA solution was removed to serve as
a standard. Patients then fasted for a further 2h, after which
they could eat and drink freely. Urine was collected for 24 h.
The total volume of urine was noted and aliquots of 4 ml
each were counted on a Kontron gamma counter for Omin.
The percentage of 51chromium EDTA excreted over 24h
was then calculated from the formula:
cpm urine weight of standard
cpm standard weight of dose
urine volume in mls
volume of diluted standard
Creatinine was measured in the same urine sample and a
simultaneous blood sample. Creatinine clearance was
calculated to estimate renal function.
Thirty-three cancer patients (18 M; 15 F) of mean age 32
yrs (range 10-59 yrs) who had received no cytotoxic
treatment for at least I month formed the control
population. Three of these gave a history of heavy alcohol
intake immediately before testing and they were subsequently
excluded from the control group (Draper et al., 1983). In
three patients, repeated tests were possible before any
treatment was given and the results compared.
We applied the test sequentially at 5-8 day intervals in
two groups of patients:-..
1. Nineteen patients (Table I) treated with a single
injection of melphalan, i.v. with autologous bone
marrow grafting. Fifteen patients were randomly
allocated either to receive melphalan 200-200 mg m-2
or to receive a priming dose of cyclophosphamide 300-
400 mgm-2 i.v. followed by melphalan 200-220 mg m-2
seven days later. Four patients received 180 mg m- 2
alone.
2. Two patients treated with cyclophosphamide 7 gm-2
i.v. without bone marrow grafting.
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Results
Acceptability
The test was generally well tolerated. The EDTA solution is
odourless and colourless and none of the untreated patients
were unable to take it. After intensive cytotoxic treatment,
two patients were completely unable to tolerate the test
because of nausea and mouth soreness. Two patients who
are already nauseated by their cytotoxic treatment given 5
days earlier, managed to swallow the 51Cr EDTA but
remained nauseated and vomited a few hours after the test
began on this occasion and these results are excluded. They
completed the test on all other occasions and those results
are included in the analysis. In one patient the test failed on
day 15 because of nausea. She was very ill with infection,
jaundice and fluid imbalance and subsequently died. The
completeness of the urine collections in her case was
uncertain and she is excluded from analysis.
Normal range
In 30 untreated patients, the mean 24h 5"Cr EDTA
excretion in urine was 1.7% of administered dose with
standard deviation 0.58% (Figure 1). Three other untreated
patients gave a history of heavy alcohol intake and their
excretion values were 4.1, 5.6 and 5.9%. These three are
excluded from our normal range which extends up to 2.9%.
In the three untreated patients in whom the test was done
twice the results agreed closely.
Duration ofexcretion of 51Cr EDTA
In eight patients, urine was collected for 3 days and the daily
excretion of 51Cr EDTA estimated (Figure 2). The excretion
fell rapidly and had reached low levels during the third day.
However, a significant proportion of the dose was excreted
between 24 and 48 h for some patients and so an initial 24 h
period of collection may underestimate the total absorption
of EDTA in these patients.
Serial collections after cytotoxic treatment
The test was performed sequentially after treatment at
intervals of - 5 days.
(i) High dose melphalan (180-220 mgm-2) with autologous
marrow grafting The test became abnormal after one week
and returned to normal after two weeks (Figure 3). The data
suggest that the time of maximum increase in gut
permeability was at about day 9. All of these patients
experienced diarrhoea after their melphalan treatment,
beginning after one and continuing for about one week as
described by Cornbleet et al. (1983).
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Figure 1 Maximal 24h urinary excretion of 5tCr EDTA in
patients after i.v. melphalan 180mgm- 2 or 200-220mgm- 2
compared to untreated controls. The patients treated at the
higher dose levels were randomly allocated to cyclophosphamide
priming and the primed group have significantly lower 'Cr
EDTA excretion (P<0.01 using a t test and Fisher's exact test).
Median 24 h excretion in controls was 1.7% compared to median
maximal excretion of 3.1% in patients receiving 200-220mgm-2
melphalan with cyclophosphamide priming and 7.4% in patients
given the same melphalan dose but no priming. There were no
significant differences in timing of studies between the groups.
Gut damage increased with increased melphalan dose and
the peak abnormality was significantly greater after
melphalan 200 mg m 2 than after melphalan 180mg m-2
(P =0.05 Wilcoxon Rank Sum Test). Among patients who
received 200-220mgm 2 of melphalan, the first 8 received
200mgm 2 and the next 7 received 220mgm-2. They were
randomly allocated within each dose level to receive a
cyclophosphamide prime or not. The maximum measured
excretion of EDTA was significantly lower in the patients
who received a cyclophosphamide prime (Figure 1, P<0.01
t test and Fishers exact test).
able I
No.
patient Treatment Age Sex Diagnosis
1-4 Melphalan 180mgm-2 44-60 F Breast cancer
5 Cyclophosphamide priming and melphalan 200mgm-2 52 F Melanoma
6 Cyclophosphamide priming and melphalan 200mgm-2 42 F Breast cancer
7 Cyclophosphamide priming and melphalan 200mgm-2 26 M Hodgkin's disease
8 Cyclophosphamide priming and melphalan 200mgm2 50 F Breast cancer
9 Melphalan 200mg m-2 44 F Hodgkin's disease
10 Melphalan 200mgm-2 37 M Hodgkin's disease
11 Melphalan 200mgm-2 50 F Nasopharyngeal cancer
12 Melphalan 200mgm-2 48 F Breast cancer
13 Melphalan 220mgm-2 and cyclophosphamide 32 F Hodgkin's disease
14 Melphalan 220mgm-2 and cyclophosphamide 19 M Hodgkin's disease
15 Melphalan 220mgm-2 and cyclophosphamide 21 M Wilms tumour
16 Melphalan 220mgm-2 and cyclophosphamide 21 M Rhabdomyosarcoma
17 Melphalan 220mgm-2 42 M Angiofollicular hyperplasia
18 Melphalan 220MgM-2 42 M Hodgkin's disease
19 Melphalan 220mgM-2 21 F Soft tissue sarcomaCYCLOPHOSPHAMIDE AND MELPHALAN-INDUCED GI TRACT DAMAGE 533
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Figure 2 TwCr EDTA excretion in three sequential 24 h urine
collections after a single test dose in eight patients.
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Figure 3 Twenty-four hour excretion of 51Cr EDTA after an
oral test dose. The test was applied serially following treatment
with melphalan and autologous BMT. Four patients given
melphalan 180mgm2 .(@); four given melphalan 200mgm-2
(A); and four given cyclophosphamide 300mgm-2 followed by
melphalan 200 mgm (0).
(ii) High dose cyclophosphamide Two patients received
cyclophosphamide 7 gm-2 i.v. without bone marrow
grafting. No abnormalities were observed in their intestinal
permeability.
Renalfunction
Since renal clearance of 51Cr EDTA might be expected to
influence the speed of excretion of the absorbed oral dose,
creatinine clearance was measured on each 24 h urine.
Change in urine excretion of 51Cr EDTA in the first 24h
were not explained by changes in creatinine clearance.
Discussion
The 51Cr EDTA absorption test was easy to perform and
generally well tolerated by our patients even after intensive
cytotoxic therapies. 5"Cr edetic acid is cheap, stable and
widely used in Nuclear Medicine. The test was reliable and
had a narrow normal range although interfering factors such
as heavy alcohol intake must be identified (Bjarnason et al.,
1984). Collection of urine for longer than 24h might increase
its sensitivity but is time consuming for patients and was not
necessary for the purposes of this study.
Abnormalities due to melphalan were detected at doses
above 180 mgm-2 and seemed to be dose-dependent. The
timing of these abnormalities was similar to the timing of
histological gut abnormalities after cytotoxic treatment in
serial biopsy studies in man (Lubitz & Ekert, 1979;
Cornbleet et al., 1983). No intestinal abnormalities were
shown after cyclophosphamide treatment which is in keeping
with previous evidence for this drug (Shaw et al., 1979).
Although the numbers of patients are not great, we have
demonstrated a significant reduction in gut damage after
melphalan by cyclophosphamide priming. The effect is quite
small and probably not greater than a dose change of 20-
40mg. Its mechanism is not known (Millar & McElwain,
1985) but further investigation of mechanism and of the
optimal timing of the priming dose may allow further
reduction in gut damage.
We are grateful to Dr Ralph McCready for his support and to the
physicians of the Royal Marsden Hospital for allowing us to study
their patients.
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